Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Erenumab in Chronic Migraine Prevention
NCT02066415Phase 2Completed
- Sponsor
- Amgen
- Start
- Mar 2014
- Primary completion
- Feb 2016
- Modality
- Monoclonal Antibodies
- Countries
- 10
01
Overview
Phase 2, randomised, double-blind trial of erenumab in chronic migraine (3 arms), sponsored by Amgen. Primary endpoint: Change From Baseline in Monthly Migraine Days at 12 weeks. Started Mar 2014; status: completed.
02
Drugs
erenumab
03
Conditions
chronic migraine
Beyond the preview
Go deeper on NCT02066415.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02066415.